dc.creator | Hindi Muñiz, Nadia | es |
dc.creator | Carrasco Garcia, Irene | es |
dc.creator | Sanchez Camacho, Alberto | es |
dc.creator | Gutierrez, Antonio | es |
dc.creator | Peinado, Javier | es |
dc.creator | Rincon, Inmaculada | es |
dc.creator | Santos Fernández, Paloma | es |
dc.creator | Sánchez Bustos, Paloma | es |
dc.creator | da Silva Moura, David | es |
dc.creator | Martín Broto , Javier | es |
dc.date.accessioned | 2021-02-16T11:04:28Z | |
dc.date.available | 2021-02-16T11:04:28Z | |
dc.date.issued | 2020-12-12 | |
dc.identifier.citation | Hindi Muñiz, N., Carrasco Garcia, I., Sanchez Camacho, A., Gutierrez, A., Peinado, J., Rincon, I.,...,Martín Broto , J. (2020). Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center. Cancers, 12 (12), 1-14. | |
dc.identifier.issn | 2072-6694 | es |
dc.identifier.uri | https://hdl.handle.net/11441/105024 | |
dc.description.abstract | Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical trial in this setting. This retrospective series aims to analyze our experience with the same regimen in the real-life setting. We retrospectively reviewed advanced sarcoma patients treated with trabectedin concomitantly with radiotherapy with palliative intent. Growth-modulation index (GMI) was calculated as a surrogate of efficacy. Forty metastatic patients were analyzed. According to RECIST, there was one (2.5%) complete response, 12 (30%) partial responses, 18 (45%) disease stabilizations, and nine (22.5%) progressions. After a median follow-up of 15 months (range 2–38), median progression-free survival (PFS) and overall survival (OS) were 7.5 months (95% CI 2.8–12.2) and 23.5 months (95% CI 1.1–45.8), respectively. Median GMI was 1.42 (range 0.19–23.76), and in 16 (53%) patients, it was >1.33. In patients with GMI >1.33, median OS was significantly longer than in those with GMI 0–1.33 (median OS 52.1 months (95% CI not reached) vs. 8.9 months (95% CI 6.3–11.6), p = 0.028). The combination of trabectedin plus radiotherapy is an active therapeutic option in patients with advanced STS, especially when tumor shrinkage for symptomatic relief is needed | es |
dc.format | application/pdf | es |
dc.format.extent | 14 | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Cancers, 12 (12), 1-14. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Advanced soft-tissue sarcoma | es |
dc.subject | Trabectedin plus radiotherapy | es |
dc.subject | Palliative therapy | es |
dc.subject | Growth-modulation index | es |
dc.title | Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.relation.publisherversion | https://doi.org/10.3390/cancers12123740 | es |
dc.identifier.doi | 10.3390/cancers12123740 | es |
dc.journaltitle | Cancers | es |
dc.publication.volumen | 12 | es |
dc.publication.issue | 12 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 14 | es |